Scientists from Nanyang Technological University, Singapore (NTU Singapore) have published a groundbreaking study revealing that the brain’s internal waste removal system frequently becomes obstructed in individuals exhibiting the earliest indicators of Alzheimer’s disease. These blockages, characterized as "enlarged perivascular spaces" (EPVS), appear to significantly impair the brain’s ability to flush out metabolic toxins and harmful proteins. Crucially, the research suggests that these visible anomalies on brain scans may manifest well before the onset of clinical dementia symptoms, providing a potential window for earlier intervention and more effective management of the neurodegenerative condition.
The study, led by the Lee Kong Chian School of Medicine (LKCMedicine) at NTU, highlights a critical shift in how clinicians might approach the diagnosis of Alzheimer’s. Traditionally, the disease is diagnosed through a combination of cognitive assessments and expensive or invasive tests, such as Positron Emission Tomography (PET) scans or lumbar punctures to check cerebrospinal fluid. However, the discovery that EPVS can be identified via routine Magnetic Resonance Imaging (MRI) scans—which are already standard practice for evaluating cognitive decline—offers a cost-effective and accessible diagnostic alternative.
The Mechanics of Brain Waste Removal
To understand the significance of the findings, it is essential to look at the brain’s "glymphatic system," a functional waste clearance pathway. Within the human brain, blood vessels are enveloped by microscopic channels known as perivascular spaces. These channels serve as a plumbing system, facilitating the drainage of interstitial fluid and metabolic waste products. Among the most dangerous of these waste products are beta-amyloid and tau proteins. In a healthy brain, these proteins are efficiently cleared; however, in patients with Alzheimer’s, they accumulate to form plaques and tangles that disrupt cell communication and eventually lead to neuronal death.
When the drainage system fails or becomes less efficient, these perivascular spaces can become distended or "enlarged." While EPVS have been noted in medical literature for years, their direct correlation with the specific biochemical markers of Alzheimer’s—particularly in the pre-dementia stage—has remained a subject of intense scientific inquiry. The NTU Singapore study provides some of the most robust evidence to date that these enlarged spaces are not merely incidental findings but are active indicators of a failing clearance system linked to Alzheimer’s pathology.
Addressing the Diversity Gap in Alzheimer’s Research
One of the most significant aspects of the NTU study is its focus on Asian populations. For decades, the vast majority of clinical research regarding Alzheimer’s disease has been conducted on Caucasian cohorts in North America and Europe. This geographic and ethnic bias has long been a concern for global health experts, as the genetic and environmental factors contributing to dementia can vary significantly across different populations.
"Research has shown that dementia does not affect all ethnic groups in the same way, making region-specific studies essential," explained Associate Professor Nagaendran Kandiah, the study’s lead author and Director of the Dementia Research Centre (Singapore) at LKCMedicine. Prof Kandiah pointed out a striking genetic discrepancy: the apolipoprotein E4 (APOE4) gene, a major risk factor for Alzheimer’s, is present in approximately 50 to 60 percent of Caucasian patients with the disease. In contrast, among Singaporean dementia patients, the prevalence of this gene is less than 20 percent.
This discrepancy underscores the necessity of the Singapore-based study, which examined nearly 1,000 participants from diverse ethnic backgrounds, including Chinese, Malay, and Indian heritages. By focusing on a local cohort, the researchers have ensured that their findings are directly applicable to the Asian context, where the burden of dementia is expected to rise sharply in the coming decades due to rapidly aging populations.
Methodology and Correlation with Blood Biomarkers
The research team analyzed a cohort of nearly 1,000 individuals, categorized into two primary groups: those with normal cognitive function and those experiencing mild cognitive impairment (MCI). MCI is often considered a "prodromal" or precursor stage to dementia, where individuals experience noticeable changes in memory or thinking but can still perform daily activities.
The methodology involved a dual-pronged approach. First, participants underwent high-resolution MRI scans to identify and quantify the presence of enlarged perivascular spaces. Second, the scientists utilized advanced blood-testing technology to measure seven specific biochemical markers associated with Alzheimer’s, including various forms of amyloid-beta and tau proteins, as well as markers of axonal damage and neuroinflammation.
The results were definitive. Participants with mild cognitive impairment were significantly more likely to exhibit a higher volume of enlarged perivascular spaces compared to their cognitively healthy counterparts. Furthermore, the presence of these "clogged drains" was strongly correlated with four out of the seven blood-based biochemical markers. This link suggests that the physical enlargement of these spaces is a direct consequence of, or a contributor to, the buildup of toxic proteins in the brain.
EPVS vs. White Matter Damage: A Superior Early Signal
The study also compared EPVS with white matter hyperintensities (WMH), which are areas of damage to the brain’s white matter often caused by small vessel disease or reduced blood flow. While WMH is a well-established marker used by clinicians to assess dementia risk, the NTU team found that in the early stages of cognitive decline, EPVS held unique predictive value.
In participants with mild cognitive impairment, the association between Alzheimer’s-related biochemicals and enlarged perivascular spaces was notably stronger than the association with white matter damage. This finding suggests that EPVS may serve as a more sensitive and earlier indicator of Alzheimer’s pathology than the markers currently prioritized in clinical settings.
Justin Ong, a fifth-year medical student at LKCMedicine and the study’s first author, emphasized the clinical utility of this discovery. "Identifying Alzheimer’s sooner gives doctors more time to intervene and potentially slow the progression of symptoms such as memory loss, reduced thinking speed, and mood changes," Ong stated. The research was born out of the Scholarly Project module, a core component of NTU’s Bachelor of Medicine and Bachelor of Surgery (MBBS) programme, highlighting the institution’s commitment to integrating undergraduate education with high-impact scientific discovery.
Expert Reactions and Clinical Implications
The medical community has reacted with optimism to the findings. Dr. Rachel Cheong Chin Yee, a Senior Consultant at Khoo Teck Puat Hospital’s Department of Geriatric Medicine, noted that the study clarifies the role of small blood vessel changes in the development of Alzheimer’s. "These findings are significant because they suggest that brain scans showing enlarged perivascular spaces could potentially help identify people at higher risk of Alzheimer’s disease, even before symptoms appear," said Dr. Cheong, who was not part of the research team.
Similarly, Dr. Chong Yao Feng, a Consultant at the National University Hospital’s Division of Neurology, observed that the study challenges the traditional separation of cerebrovascular disease and Alzheimer’s disease. "The study’s findings are intriguing as they demonstrate that both diseases do interact in a synergistic manner," Dr. Chong remarked. He cautioned that when doctors see EPVS on an MRI, they should not automatically assume it is a benign sign of aging or purely a blood vessel issue; rather, it may be a signal of underlying Alzheimer’s risk that warrants further investigation.
The Path Toward Early Intervention and Treatment
The ability to detect Alzheimer’s early is more critical now than ever before. Recent years have seen the emergence of disease-modifying therapies, such as monoclonal antibodies targeting amyloid plaques. These treatments are generally most effective when administered during the early stages of the disease, before widespread and irreversible neuronal damage has occurred.
By utilizing routine MRI scans to identify EPVS, healthcare systems could potentially implement screening protocols that catch the disease years before a patient would otherwise receive a diagnosis. This "democratization" of early detection—moving it away from specialized research centers and into general neurology and geriatric clinics—could significantly improve patient outcomes on a global scale.
Future Research and Longitudinal Outlook
Despite the promising results, the NTU researchers acknowledge that further validation is required. The team plans to conduct longitudinal follow-ups with the study participants to track their cognitive trajectories over several years. This will allow the scientists to determine exactly how many of those with enlarged perivascular spaces eventually progress to full-blown Alzheimer’s dementia.
If these future studies confirm that EPVS is a reliable predictor of disease progression, it could lead to the development of standardized scoring systems for perivascular spaces on MRI reports. Such a system would provide radiologists and neurologists with a clear framework for assessing a patient’s risk profile during routine check-ups.
As the global population ages, the prevalence of Alzheimer’s is projected to triple by 2050. Discoveries like those made at NTU Singapore are essential in the race to find scalable, affordable, and accurate ways to manage this looming public health crisis. By looking closely at the "plumbing" of the brain, researchers are opening new doors to understanding, treating, and perhaps eventually preventing the most common form of dementia in the world.
